In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens

Souli, Maria; Wennersten, Christine; Eliopoulos, George M.

doi:10.1016/s0924-8579(98)00020-x

Cited by 52 publications

(26 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is reported that bacteria have developed a new kind of b-lactamase that gives resistance against b-lactam antibiotics. [17][18][19] Some approaches to overcome bacterial resistance have been developed such as to change the structure of b-lactam moiety of antibiotics [20][21][22] and to synthesize new antibiotics of high efficiency [23][24][25][26] although these methods are time consuming and are often not economically feasible.…”

Section: Introductionmentioning

confidence: 99%

Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings

2010

View full text Add to dashboard Cite

We report a one-pot synthesis of spherical gold nanoparticles (52-22 nm) and their capping with cefaclor, a second-generation antibiotic, without use of other chemicals. The differently sized gold nanoparticles were fabricated by controlling the rate of reduction of gold ions in aqueous solution by varying the reaction temperature (20-70 C). The primary amine group of cefaclor acted as both the reducing and capping agent for the synthesis of gold nanoparticles leaving the b-lactam ring of cefaclor available for activity against microbes. Antimicrobial testing showed that cefaclor reduced gold nanoparticles have potent antimicrobial activity against both Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria as compared to cefaclor or gold nanoparticles alone. The minimum inhibition concentrations (MICs) of cefaclor reduced gold nanoparticles were 10 mg mL À1and 100 mg mL À1 for S. aureus and E. coli respectively. The cefaclor reduced gold nanoparticles were further coated onto poly(ethyleneimine) (PEI) modified glass surfaces to obtain antimicrobial coatings suitable for biomedical applications and were tested against E. coli as an exemplar of activity. The antimicrobial coatings were very robust under adverse conditions (pH 3 and 10), inhibited the growth of E. coli on their surfaces, and could be used many times with retained activity. Results from a combined spectroscopic (FTIR) and microscopic study (AFM) suggest that the action of these novel particles is through the combined action of cefaclor inhibiting the synthesis of the peptidoglycan layer and gold nanoparticles generating ''holes'' in bacterial cell walls thereby increasing the permeability of the cell wall, resulting in the leakage of cell contents and eventually cell death.

show abstract

Section: Introductionmentioning

confidence: 99%

Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings

2010

View full text Add to dashboard Cite

show abstract

“…Colony counts were performed. To determine if there were antibiotic carryover effects of ABT-492, ciprofloxacin, and moxifloxacin, experiments were performed as previously described (19,24). No antibiotic carryover effects of ABT-492 and ciprofloxacin were observed.…”

mentioning

confidence: 99%

In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms

Almer

Hoffrage

Keller

et al. 2004

Antimicrob Agents Chemother

View full text Add to dashboard Cite

In vitro activities of ABT-492, ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin were compared. ABT-492 was more potent against quinolone-susceptible and -resistant grampositive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. Bactericidal activity of ABT-492 was also evaluated.Antimicrobial resistance continues to be problematic. Resistance rates in other U.S. studies were examined. More than 30% of Streptococcus pneumoniae clinical isolates are penicillin nonsusceptible, and approximately 25% are macrolide resistant (7, 10). In Haemophilus influenzae, ␤-lactamase-mediated ampicillin resistance is about 28% (11). In uncomplicated urinary tract infections, 10 to 20% of Escherichia coli isolates are resistant to trimethoprim-sulfamethoxazole and 33 to 40% are resistant to ampicillin (8, 13). Methicillin resistance in nosocomial Staphylococcus aureus has increased from 2.1% to 26-44%, and methicillin-resistant S. aureus (MRSA) is becoming a problem in community-acquired infections (1, 9, 22, 23).Fluoroquinolones have broad-spectrum activity. Newer quinolones demonstrate increased potency against S. pneumoniae, staphylococci, H. influenzae, and some enterococci and have a potency equivalent to that of ciprofloxacin against members of the family Enterobacteriaceae (3,5,12,15,16). In the United States, quinolone resistance remains low in S. pneumoniae and has been reported only rarely in H. influenzae (2,6,14,25).ABT-492 is a new fluoroquinolone with increased activity, compared to levofloxacin, trovafloxacin, and ciprofloxacin, against gram-positive organisms and activity similar to that of ciprofloxacin against certain gram-negative, quinolone-susceptible and -resistant organisms (20). The in vitro activities of ABT-492, moxifloxacin, gatifloxacin, gemifloxacin, levofloxacin, trovafloxacin, and ciprofloxacin were evaluated against 919 quinolone-susceptible and -resistant gram-positive and gramnegative pathogens. MIC ranges and MICs inhibiting 50% (MIC 50 ) and 90% (MIC 90 ) of the tested strains are shown in Table 1. Time-kill analyses of ABT-492, ciprofloxacin, and moxifloxacin were also performed.Clinical isolates dating from 1983 to 2000 from the Abbott culture collection and reference strains from the American Type Culture Collection (Manassas, Va.) were tested. Strains were classified as quinolone susceptible or resistant on the basis of levofloxacin or ciprofloxacin susceptibility for grampositive and gram-negative organisms, respectively, according to the interpretive criteria of the National Committee for Clinical Laboratory Standards (NCCLS) (17).ABT-492 and comparator quinolones were synthesized at Abbott Laboratories (Abbott Park, Ill.). Penicillin and oxacillin were purchased from Sigma Chemical Company (St. Louis, Mo.).MIC determinations and quality control tests were performed by the NCCLS broth mi...

show abstract

“…Levofloxacin (a broad-spectrum fluoroquinolone) is the optically active L isomer of the racemate ofloxacin. Levofloxacin has activity against gram-negative bacteria similar to that of ciprofloxacin or ofloxacin and has a greater potency in vitro against gram-positive bacteria (8,10,24).…”

mentioning

confidence: 99%

Effectiveness of Ciprofloxacin, Levofloxacin, or Moxifloxacin for Treatment of Experimental Staphylococcus aureus Keratitis

Dajcs

Thibodeaux

Marquart

et al. 2004

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of Staphylococcus aureus isolates of diverse antibiotic susceptibilities. Rabbit eyes were intrastromally injected with approximately 100 CFU of methicillinsensitive or methicillin-resistant S. aureus (MSSA or MRSA, respectively) organisms that were either sensitive or resistant to ofloxacin. One drop of moxifloxacin (0.5%), levofloxacin (0.5%), or ciprofloxacin (0.3%) was topically applied hourly from 4 to 9 (early) or 10 to 15 (late) h postinfection. At 1 h after cessation of therapy, the corneas were harvested, and the number of CFU per cornea was determined. For the ofloxacin-sensitive strains, early treatment of MSSA or MRSA with moxifloxacin, levofloxacin, or ciprofloxacin produced approximately a 5-log decrease in CFU per cornea relative to that in untreated eyes (P < 0.0001). For late therapy of ofloxacin-sensitive strains, moxifloxacin, levofloxacin, and ciprofloxacin produced approximately 5-, 4-, and 2-to 3-log reductions in CFU per cornea, respectively (P < 0.0001). Early treatment of the ofloxacin-resistant strains with either moxifloxacin or levofloxacin produced a >4-log or >3-log decrease, respectively, in the MSSA or MRSA strains (P < 0.0001), whereas ciprofloxacin treatment produced a 1-log decrease in CFU per cornea relative to that in untreated eyes (P ‫؍‬ 0.1540). For late treatment of ofloxacin-resistant strains, levofloxacin and ciprofloxacin failed to significantly reduce the number of CFU per cornea (P > 0.3627), whereas moxifloxacin produced a significant reduction in CFU per cornea of approximately 1 log (P < 0.0194). Therefore, for three of the four treatments tested, moxifloxacin demonstrated greater effectiveness than either levofloxacin or ciprofloxacin.

show abstract

In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens

Cited by 52 publications

References 24 publications

Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings

Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings

In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms

Effectiveness of Ciprofloxacin, Levofloxacin, or Moxifloxacin for Treatment of Experimental Staphylococcus aureus Keratitis

Contact Info

Product

Resources

About